Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 11/30/14
Due: 11/30/15
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 01/11/17
Due: 01/11/18
Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
Phase: N/A
Priority: Normal
Start: 04/13/18
End: 11/11/20
Due: 11/11/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary | NCT01584297 | Grupo Español de Tumores Huérfanos e Infrecuentes | user2@example.com | None | 2012-10-31 | 2014-11-30 | 2015-11-30 | - | - | 2025-07-14 |
| Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. | NCT02101684 | Grupo Español de Tumores Huérfanos e Infrecuentes | user2@example.com | None | 2014-06-30 | 2017-01-11 | 2018-01-11 | - | - | 2025-07-14 |
| Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study | NCT03464201 | Grupo Español de Tumores Huérfanos e Infrecuentes | user2@example.com | None | 2018-04-13 | 2020-11-11 | 2021-11-11 | - | - | 2025-07-14 |